136 related articles for article (PubMed ID: 18578033)
1. FDA notifications. Fosamprenavir label is updated.
AIDS Alert; 2008 Feb; 23(2):21-2. PubMed ID: 18578033
[No Abstract] [Full Text] [Related]
2. FDA notifications. Agenerase product label changed.
AIDS Alert; 2002 Oct; 17(10):131. PubMed ID: 12400469
[No Abstract] [Full Text] [Related]
3. Lexiva (fosamprenavir) approved.
AIDS Treat News; 2003 Oct; (395):2. PubMed ID: 14666909
[TBL] [Abstract][Full Text] [Related]
4. FDA grants approval to fosamprenavir calcium.
AIDS Alert; 2004 Jan; 19(1):11-2. PubMed ID: 14974421
[TBL] [Abstract][Full Text] [Related]
5. FDA notifications. FDA approves NDA for Lexiva.
AIDS Alert; 2007 Dec; 22(12):142. PubMed ID: 18415960
[No Abstract] [Full Text] [Related]
6. FDA notifications. FDA approves new formulation of Lexiva.
AIDS Alert; 2007 Aug; 22(8):90-1. PubMed ID: 17768778
[No Abstract] [Full Text] [Related]
7. Lower dose of ritonavir approved for use with fosamprenavir.
Sax PE
AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
[No Abstract] [Full Text] [Related]
8. Anti-HIV agents. Saquinavir with fosamprenavir.
TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17219609
[No Abstract] [Full Text] [Related]
9. FDA approves Lexiva.
IAPAC Mon; 2003 Nov; 9(11):280. PubMed ID: 14989187
[No Abstract] [Full Text] [Related]
10. FDA notifications. Revised atazanavir package insert.
AIDS Alert; 2008 Mar; 23(3):35-6. PubMed ID: 18661642
[No Abstract] [Full Text] [Related]
11. Favourable use of non-boosted fosamprenavir in patients treated with warfarin.
Honda H; Gatanaga H; Matsumura J; Kamimura M; Goto K; Tsukada K; Honda M; Teruya K; Kikuchi Y; Oka S
Int J STD AIDS; 2009 Jun; 20(6):441. PubMed ID: 19451340
[No Abstract] [Full Text] [Related]
12. FDA notifications. Kaletra revisions to packaging approved.
AIDS Alert; 2010 Mar; 25(3):34. PubMed ID: 20629261
[No Abstract] [Full Text] [Related]
13. FDA notifications. Darunavir label has these changes.
AIDS Alert; 2008 Dec; 23(12):142-4. PubMed ID: 19112649
[No Abstract] [Full Text] [Related]
14. FDA notifications. Norvir label changes approved.
AIDS Alert; 2008 Oct; 23(10):115-6. PubMed ID: 18938256
[No Abstract] [Full Text] [Related]
15. FDA notifications. New risk information added to label of antiviral saquinavir.
AIDS Alert; 2010 Dec; 25(12):143-4. PubMed ID: 21328816
[No Abstract] [Full Text] [Related]
16. FDA notifications. Labeling changed on Prezista.
AIDS Alert; 2010 Mar; 25(3):34-6. PubMed ID: 20632456
[No Abstract] [Full Text] [Related]
17. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.
Pea F; Tavio M; Pavan F; Londero A; Bresadola V; Adani GL; Furlanut M; Viale P
Antivir Ther; 2008; 13(5):739-42. PubMed ID: 18771060
[TBL] [Abstract][Full Text] [Related]
18. Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency.
Torres HA; Barnett BJ; Arduino RC
Clin Infect Dis; 2007 Mar; 44(6):887-8. PubMed ID: 17304468
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
20. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
